Sagimet Biosciences Inc
SGMT8.440USD
+0.190+2.30%
Market hours （ET）Quotes delayed by 15 min
USD0.000Pre-market (ET)
271.73MMarket Cap
LossP/E TTM
Sagimet Biosciences Inc
8.440
+0.190+2.30%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q2
FY2022Q1
FY2021Q1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
-134.15%-14.54M
-55.64%-11.02M
-404.49%-19.57M
1.50%-5.63M
12.37%-6.21M
---7.08M
---3.88M
6.81%-5.72M
-51.85%-7.08M
---6.14M
-79.56%-4.67M
---2.60M
Net income from continuing operations
-174.19%-18.18M
-98.76%-16.20M
-130.11%-14.62M
-19.65%-8.12M
-0.64%-6.63M
---8.15M
---6.35M
4.46%-6.79M
24.59%-6.59M
---7.10M
-119.31%-8.73M
---3.98M
Other non-cash items
-215.92%-496.00K
-150.00%-19.00K
-1500.00%-490.00K
-1573.33%-442.00K
-15600.00%-157.00K
--38.00K
--35.00K
433.33%30.00K
-103.13%-1.00K
---9.00K
6.67%32.00K
--30.00K
Change in working capital
1571.82%2.66M
1426.81%3.66M
-1128.42%-6.01M
7133.33%1.48M
85.69%-181.00K
---276.00K
--584.00K
-103.56%-21.00K
-134.63%-1.27M
--590.00K
257.79%3.65M
--1.02M
-Change in prepaid expenses
-207.34%-687.00K
679.36%3.26M
-463.27%-4.31M
-0.97%408.00K
1829.73%640.00K
---562.00K
---765.00K
520.41%412.00K
-102.39%-37.00K
---98.00K
890.38%1.54M
--156.00K
-Change in payables and accrued expense
533.50%3.39M
38.75%444.00K
-219.42%-1.66M
374.81%1.09M
34.45%-782.00K
--320.00K
--1.39M
-155.99%-397.00K
-155.33%-1.19M
--709.00K
140.63%2.16M
--896.00K
-Change in other current liabilities
----
----
----
----
----
--4.00K
---4.00K
----
----
----
----
----
Cash from non-recurring investing activities
Cash from operating activities
-134.15%-14.54M
-55.64%-11.02M
-404.49%-19.57M
1.50%-5.63M
12.37%-6.21M
---7.08M
---3.88M
6.81%-5.72M
-51.85%-7.08M
---6.14M
-79.56%-4.67M
---2.60M
Investing cash flow
Net cash flow from investment products
13.77%3.41M
150.20%9.85M
--624.00K
-687.16%-75.16M
-84.54%3.00M
---19.62M
--0.00
--12.80M
--19.40M
----
--0.00
----
Cash from non-current investing activities
Net cash flow from investing activities
13.77%3.41M
150.20%9.85M
--624.00K
-687.16%-75.16M
-84.54%3.00M
---19.62M
--0.00
130.88%12.80M
--19.40M
---41.45M
--0.00
----
Financing cash flow
Cash flow from continuous financing activities
-100.00%0.00
--0.00
-100.00%0.00
97.03%-27.00K
77192.65%104.85M
--0.00
--87.21M
-2933.33%-910.00K
-1233.33%-136.00K
---30.00K
--12.00K
--0.00
Net cash flow from common stock issuance/repurchase
-100.00%0.00
--0.00
--0.00
--0.00
--105.75M
----
----
----
----
----
----
----
Net cash flow from preferred stock issuance/repurchase
----
----
----
----
----
----
----
----
----
----
----
--0.00
Proceeds from stock option exercised by employees
-100.00%0.00
--0.00
-100.00%0.00
--0.00
--114.00K
--0.00
--6.00K
--0.00
-100.00%0.00
--0.00
--12.00K
--0.00
Net cash flow from other financing activities
100.00%0.00
--0.00
-100.00%0.00
97.03%-27.00K
-648.53%-1.02M
--0.00
--87.21M
-2933.33%-910.00K
---136.00K
---30.00K
--0.00
----
Net cash from non-recurrent financing activities
Net cash from financing activities
-100.00%0.00
--0.00
-100.00%0.00
97.03%-27.00K
77192.65%104.85M
--0.00
--87.21M
-2933.33%-910.00K
-1233.33%-136.00K
---30.00K
--12.00K
--0.00
Net cash flow
Beginning cash balance
0.93%75.84M
-24.38%77.01M
418.47%95.96M
1332.78%176.78M
47456.33%75.14M
--101.84M
--18.51M
-76.31%12.34M
-99.72%158.00K
--52.08M
455.53%56.73M
--10.21M
Current period cash flow changes
-110.94%-11.12M
95.60%-1.17M
-122.73%-18.95M
-1409.85%-80.82M
734.47%101.64M
---26.70M
--83.33M
112.96%6.17M
361.77%12.18M
---47.61M
-79.10%-4.65M
---2.60M
Ending cash balance
-63.39%64.72M
0.93%75.84M
-24.38%77.01M
418.47%95.96M
1332.78%176.78M
--75.14M
--101.84M
314.61%18.51M
-76.31%12.34M
--4.46M
583.98%52.08M
--7.61M
Free cash flow
-134.15%-14.54M
-55.64%-11.02M
-404.49%-19.57M
1.50%-5.63M
12.37%-6.21M
---7.08M
---3.88M
---5.72M
-51.85%-7.08M
----
---4.67M
----
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
--
--
